Research Study

A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Principal Investigator 
Sunil Kalia

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT03363854
Status 
Closed for Recruitment
Study Start/End 
Jun 13, 2018 to Apr 30, 2020
Locations 
Vancouver General Hospital
Phone 
604-875-5296
Purpose of Study 

The purpose of this study is to demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.